Methylene Blue Reduced Abnormal Tau Accumulation in P301L Tau Transgenic Mice

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Hosokawa, Masato ^a   Arai, Tetsuaki ^a,b   Masuda Suzukake, Masami ^a   Nonaka, Takashi ^a   Yamashita, Makiko ^a   Akiyama, Haruhiko ^a   Hasegawa, Masato ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLENE BLUE; TAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; FRACTIONATION; IMMUNOBLOTTING; MOUSE; NONHUMAN; PROTEIN ANALYSIS; TAUOPATHY; TRANSGENIC MOUSE; WESTERN BLOTTING;

AMINO ACID SUBSTITUTION; ANIMALS; BRAIN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; METHYLENE BLUE; MICE; MICE, TRANSGENIC; MUTANT PROTEINS; PHOSPHORYLATION; PROTEIN STRUCTURE, QUATERNARY; SARCOSINE; SOLUBILITY; SUBCELLULAR FRACTIONS; TAU PROTEINS;

MUS; MUS MUSCULUS;

EID: 84871446624     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052389     Document Type: Article

References (26)

1. Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR, (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A 93: 11213-11218.
2. Taniguchi S, Suzuki N, Masuda M, Hisanaga S, Iwatsubo T, et al. (2005) Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem 280: 7614-7623.
3. Wischik CM, Bentham P, Wischik DJ, Seng KM, (2008) Tau aggregation inhibitor (TAI) therapy with Rember arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. Alzheimer's & Dementia 8: T167.
4. Gravitz L, (2011) Drugs: a tangled web of targets. Nature 475: S9-11.
5. van Bebber F, Paquet D, Hruscha A, Schmid B, Haass C, (2010) Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish. Neurobiol Dis 39: 265-271.
6. Harrington C, Rickard JE, Horsley D, Harrington KA, Hindley KP, et al. (2008) Methylthioninium chloride (MTC) acts as a tau aggregation inhibitor (TAI) in a cellular model and reverses tau pathology in transgenic mouse models of Alzheimer's disease. Alzheimer's & Dementia 4: T120-T121.
7. Congdon EE, Wu JW, Myeku N, Figueroa YH, Herman M, et al. (2012) Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy 8: 609-622.
8. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, et al. (2000) Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet 25: 402-405.
9. Wolozin B, Davies P, (1987) Alzheimer-related neuronal protein A68: specificity and distribution. Ann Neurol 22: 521-526.
10. Greenberg SG, Davies P, (1990) A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci U S A 87: 5827-5831.
11. Yamashita M, Nonaka T, Arai T, Kametani F, Buchman VL, et al. (2009) Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett 583: 2419-2424.
12. Medina DX, Caccamo A, Oddo S, (2011) Methylene blue reduces abeta levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol 21: 140-149.
13. Necula M, Breydo L, Milton S, Kayed R, van der Veer WE, et al. (2007) Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry 46: 8850-8860.
14. Kucukkilinc T, Ozer I, (2007) Multi-site inhibition of human plasma cholinesterase by cationic phenoxazine and phenothiazine dyes. Arch Biochem Biophys 461: 294-298.
15. Chies AB, Custodio RC, de Souza GL, Correa FM, Pereira OC, (2003) Pharmacological evidence that methylene blue inhibits noradrenaline neuronal uptake in the rat vas deferens. Pol J Pharmacol 55: 573-579.
16. Heiberg IL, Wegener G, Rosenberg R, (2002) Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats. Behav Brain Res 134: 479-484.
17. Gonzalez-Lima F, Bruchey AK, (2004) Extinction memory improvement by the metabolic enhancer methylene blue. Learn Mem 11: 633-640.
18. Wrubel KM, Riha PD, Maldonado MA, McCollum D, Gonzalez-Lima F, (2007) The brain metabolic enhancer methylene blue improves discrimination learning in rats. Pharmacol Biochem Behav 86: 712-717.
19. Visarius TM, Stucki JW, Lauterburg BH, (1997) Stimulation of respiration by methylene blue in rat liver mitochondria. FEBS Lett 412: 157-160.
20. Atamna H, Nguyen A, Schultz C, Boyle K, Newberry J, et al. (2008) Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J 22: 703-712.
21. Kristiansen JE, (1989) Dyes, antipsychotic drugs, and antimicrobial activity. Fragments of a development, with special reference to the influence of Paul Ehrlich. Dan Med Bull 36: 178-185.
22. Mansouri A, Lurie AA, (1993) Concise review: methemoglobinemia. Am J Hematol 42: 7-12.
23. Schneider F, Lutun P, Hasselmann M, Stoclet JC, Tempe JD, (1992) Methylene blue increases systemic vascular resistance in human septic shock. Preliminary observations. Intensive Care Med 18: 309-311.
24. Preiser JC, Lejeune P, Roman A, Carlier E, De Backer D, et al. (1995) Methylene blue administration in septic shock: a clinical trial. Crit Care Med 23: 259-264.
25. Schirmer RH, Coulibaly B, Stich A, Scheiwein M, Merkle H, et al. (2003) Methylene blue as an antimalarial agent. Redox Rep 8: 272-275.
26. Rengelshausen J, Burhenne J, Frohlich M, Tayrouz Y, Singh SK, et al. (2004) Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. Eur J Clin Pharmacol 60: 709-715.